FDA panel to consider psychedelic party drug MDMA, or molly, for PTSD

On June 4, the FDA's panel of independent advisers will review MDMA-assisted therapy for PTSD, potentially the first new treatment in this category in 25 years. Lykos Therapeutics, previously known as MAPS, has conducted two late-stage studies on MDMA, known as ecstasy or molly, which is intended to be used with psychological interventions. This marks a significant step as no psychedelic-based therapy has yet been approved in the U.S. for any condition.